Status:
TERMINATED
Ketogenic Diet With Concurrent Chemoradiation for Pancreatic Cancer
Lead Sponsor:
University of Iowa
Collaborating Sponsors:
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Conditions:
Pancreatic Neoplasms
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study investigates if using a very low carbohydrate diet during combined chemotherapy and radiation therapy is safe and if it can be tolerated by patients.
Detailed Description
Standard treatment for pancreatic cancer includes chemotherapy concurrent with radiation therapy (chemoradiation). This study is a phase I trial to determine the safety of dietary manipulation during...
Eligibility Criteria
Inclusion
- Patients must have a cytological or histological diagnosis of adenocarcinoma arising in the pancreas. Adenosquamous cancers will be acceptable.
- Cancer should be staged via AJCC as IIA, IIB, or III (T3 or T4, any N, M0)
- Age ≥ 18 years
- ECOG performance status 0-2 (Karnofsky \> 50%, see Appendix A).
- Hypertensive medication should be initiated or increased for optimal blood pressure control according to standard public health guidelines prior to starting the ketogenic diet.
- Patients must have normal organ and marrow function as defined below:
- leukocytes ≥ 3,000/mm3
- absolute neutrophil count ≥ 1,500/mm3
- platelets ≥ 100,000/mm3
- total bilirubin \< 3.0 mg/dl
- Hgb A1C \< or = to 8%
- AST(SGOT) \< or = 5 X institutional upper limit of normal OR a stable or a decreasing test value in patients who have undergone placement of an intrabiliary stent. Both the treating radiation oncologist and medical oncologist must agree that the potential subject's test value is acceptable for study accrual.
- creatinine \< 1.5 X institutional upper limit of normal OR creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
- Not pregnant. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion
- Prior abdominal radiotherapy.
- Prior therapy, with the intent to treat, the current diagnosis of pancreatic cancer.
- Known G6PD (glucose-6-phosphate dehydrogenase) deficiency.
- Patients on corticosteroids for any reason.
- Living alone at time of diet initiation.
- Other investigational agents/therapy with the intention to treat the disease under study (observational or imaging trials are acceptable).
- Uncontrolled diabetes defined as a hemoglobin A1C level \> 8% (therapeutic action is indicated at greater than 8%).
- Diabetes mellitus is not exclusionary provided the patient is not maintained with either oral medications or insulin.
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness/social situations, or any other condition that would limit compliance with study requirements as determined by study team members.
- Pregnant or lactating women: The risks of radiation and chemotherapy to a fetus are well documented.
- Female and male patients of all ethnic groups will be eligible for treatment in these protocols.
Key Trial Info
Start Date :
July 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2017
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT01419483
Start Date
July 1 2011
End Date
July 1 2017
Last Update
January 8 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Holden Comprehensive Cancer Center
Iowa City, Iowa, United States, 52242